kynurenine has been researched along with Psychoses in 16 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the last decade, there has been growing evidence that an interaction exists between inflammation and the kynurenine pathway in schizophrenia." | 9.05 | Effects of inflammation on the kynurenine pathway in schizophrenia - a systematic review. ( Elyamany, O; Mulert, C; Pedraz-Petrozzi, B; Rummel, C, 2020) |
| "Evidence, largely obtained from peripheral studies, suggests that alterations in the kynurenine pathway contribute to the aetiology of depression and disorders involving psychosis." | 8.12 | Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology. ( Brown, AM; Brown, SJ; Huang, XF; Newell, KA; Purves-Tyson, TD; Shannon Weickert, C, 2022) |
| "Although prone to residual confounding, the present results suggest the kynurenine pathway of tryptophan metabolism, noradrenergic and purinergic system dysfunction as trait factors in schizophrenia spectrum and bipolar disorders." | 7.96 | Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders. ( Agartz, I; Andreassen, OA; Bogdanov, M; Dieset, I; Djurovic, S; Hope, S; Jönsson, EG; Kaddurah-Daouk, R; Matson, W; Melle, I; Smeland, OB; Steen, NE; Vedal, TSJ, 2020) |
| "Abnormalities in the kynurenine pathway (KP) of tryptophan degradation, leading to the dysfunction of neuroactive KP metabolites in the brain, have been implicated in the pathophysiology of schizophrenia (SZ)." | 7.88 | Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia. ( Chiappelli, J; Hong, LE; Notarangelo, FM; Pocivavsek, A; Rowland, LM; Schwarcz, R; Thomas, MAR, 2018) |
| "Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society." | 7.01 | Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies. ( Bosia, M; Comai, S; Guillemin, GJ; Sapienza, J; Spangaro, M, 2023) |
| "In the last decade, there has been growing evidence that an interaction exists between inflammation and the kynurenine pathway in schizophrenia." | 5.05 | Effects of inflammation on the kynurenine pathway in schizophrenia - a systematic review. ( Elyamany, O; Mulert, C; Pedraz-Petrozzi, B; Rummel, C, 2020) |
| "Evidence, largely obtained from peripheral studies, suggests that alterations in the kynurenine pathway contribute to the aetiology of depression and disorders involving psychosis." | 4.12 | Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology. ( Brown, AM; Brown, SJ; Huang, XF; Newell, KA; Purves-Tyson, TD; Shannon Weickert, C, 2022) |
| "Risks of autoimmune processes causing schizophrenia are associated with several factors: an impaired functioning of dopaminergic and glutamatergic systems in the brain, kynurenine pathway disorder with overproduction of quinolinic, anthranilic, and kynurenic acids (possibly altering both neurons and T-regulators), increased intestinal permeability, as well as food antigens' effects, stress and infections with various pathogens at different stages of ontogenesis." | 4.02 | Autoimmune Concept of Schizophrenia: Historical Roots and Current Facets. ( Butoma, BG; Churilov, LP; Gilburd, B; Mayorova, MA; Petrova, NN; Shoenfeld, Y, 2021) |
| "Although prone to residual confounding, the present results suggest the kynurenine pathway of tryptophan metabolism, noradrenergic and purinergic system dysfunction as trait factors in schizophrenia spectrum and bipolar disorders." | 3.96 | Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders. ( Agartz, I; Andreassen, OA; Bogdanov, M; Dieset, I; Djurovic, S; Hope, S; Jönsson, EG; Kaddurah-Daouk, R; Matson, W; Melle, I; Smeland, OB; Steen, NE; Vedal, TSJ, 2020) |
| "Abnormalities in the kynurenine pathway (KP) of tryptophan degradation, leading to the dysfunction of neuroactive KP metabolites in the brain, have been implicated in the pathophysiology of schizophrenia (SZ)." | 3.88 | Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia. ( Chiappelli, J; Hong, LE; Notarangelo, FM; Pocivavsek, A; Rowland, LM; Schwarcz, R; Thomas, MAR, 2018) |
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "The kynurenine pathway of tryptophan degradation may serve to integrate disparate abnormalities heretofore identified in research aiming to elucidate the complex aetiopathogenesis of psychotic disorders." | 3.75 | Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. ( Barry, S; Clarke, G; Dinan, TG; Scully, P, 2009) |
| "Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society." | 3.01 | Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies. ( Bosia, M; Comai, S; Guillemin, GJ; Sapienza, J; Spangaro, M, 2023) |
| "Kynurenine was significantly lower in patients with PP and PD as compared to healthy postpartum women (p=0." | 1.43 | Tryptophan pathway alterations in the postpartum period and in acute postpartum psychosis and depression. ( Bergink, V; Burgerhout, KM; Drexhage, HA; Hoogendijk, WJ; Kushner, SA; Myint, AM; Schütze, G; Schwarz, MJ; Veen, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, SJ | 1 |
| Brown, AM | 1 |
| Purves-Tyson, TD | 1 |
| Huang, XF | 1 |
| Shannon Weickert, C | 1 |
| Newell, KA | 1 |
| Sapienza, J | 3 |
| Spangaro, M | 3 |
| Guillemin, GJ | 3 |
| Comai, S | 3 |
| Bosia, M | 3 |
| Pedraz-Petrozzi, B | 1 |
| Elyamany, O | 1 |
| Rummel, C | 1 |
| Mulert, C | 1 |
| Mayorova, MA | 1 |
| Butoma, BG | 1 |
| Churilov, LP | 1 |
| Gilburd, B | 1 |
| Petrova, NN | 1 |
| Shoenfeld, Y | 1 |
| Wurfel, BE | 1 |
| Drevets, WC | 1 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 1 |
| Morris, HM | 1 |
| Teague, TK | 1 |
| Dantzer, R | 1 |
| Savitz, JB | 1 |
| Chiappelli, J | 1 |
| Notarangelo, FM | 1 |
| Pocivavsek, A | 1 |
| Thomas, MAR | 1 |
| Rowland, LM | 1 |
| Schwarcz, R | 1 |
| Hong, LE | 1 |
| Li, C | 1 |
| Wang, A | 1 |
| Wang, C | 1 |
| Ramamurthy, J | 1 |
| Zhang, E | 1 |
| Guadagno, E | 1 |
| Trakadis, Y | 1 |
| De Picker, L | 1 |
| Ottoy, J | 1 |
| Verhaeghe, J | 1 |
| Deleye, S | 1 |
| Wyffels, L | 1 |
| Fransen, E | 1 |
| Kosten, L | 1 |
| Sabbe, B | 1 |
| Coppens, V | 1 |
| Timmers, M | 1 |
| de Boer, P | 1 |
| Van Nueten, L | 1 |
| Op De Beeck, K | 1 |
| Oberacher, H | 1 |
| Vanhoenacker, F | 1 |
| Ceyssens, S | 1 |
| Stroobants, S | 1 |
| Staelens, S | 1 |
| Morrens, M | 1 |
| Curto, M | 1 |
| Lionetto, L | 1 |
| Fazio, F | 1 |
| Corigliano, V | 1 |
| Comparelli, A | 1 |
| Ferracuti, S | 1 |
| Simmaco, M | 1 |
| Nicoletti, F | 1 |
| Baldessarini, RJ | 1 |
| Steen, NE | 1 |
| Dieset, I | 1 |
| Hope, S | 1 |
| Vedal, TSJ | 1 |
| Smeland, OB | 1 |
| Matson, W | 1 |
| Kaddurah-Daouk, R | 2 |
| Agartz, I | 1 |
| Melle, I | 1 |
| Djurovic, S | 1 |
| Jönsson, EG | 1 |
| Bogdanov, M | 1 |
| Andreassen, OA | 1 |
| Shilov, IuE | 1 |
| Bezrukov, MV | 1 |
| Veen, C | 1 |
| Myint, AM | 1 |
| Burgerhout, KM | 1 |
| Schwarz, MJ | 1 |
| Schütze, G | 1 |
| Kushner, SA | 1 |
| Hoogendijk, WJ | 1 |
| Drexhage, HA | 1 |
| Bergink, V | 1 |
| Barry, S | 1 |
| Clarke, G | 1 |
| Scully, P | 1 |
| Dinan, TG | 1 |
| Müller, N | 1 |
| Condray, R | 1 |
| Dougherty, GG | 1 |
| Keshavan, MS | 1 |
| Reddy, RD | 1 |
| Haas, GL | 1 |
| Montrose, DM | 1 |
| Matson, WR | 1 |
| McEvoy, J | 1 |
| Yao, JK | 1 |
| HEELEY, AF | 1 |
| ROBERTS, GE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Kynurenine Pathway Metabolites as Novel Translational Biological Markers of Irritable Bowel Syndrome: Relationship to Gastrointestinal Function, Cognition and Co-morbid Depression[NCT01304355] | 85 participants (Anticipated) | Observational | 2011-01-31 | Recruiting | |||
| A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia[NCT02796859] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| An Open-Label Trial of Tocilizumab in Schizophrenia[NCT01696929] | Phase 1 | 8 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Brief Assessment of Cognition in Schizophrenia (BACS) is the metric used to characterize cognition in this study. The BACS consists of 6 subscales: Verbal Memory (range 0-75), Working Memory (range 0-28), Motor Speed (range 0-100), Verbal Fluency (measure is total number of words generated in two 60 second trials), Attention and Processing speed (range 0-110), and Executive Function (range 0-22). For each subscale, higher scores reflect better cognition. For each subscale, a Standard Deviation Score was calculated based on normative data (Keefe et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research 102 (2008) 108-115). The BACS composite score is calculated as the average Standard Deviation Score of the 6 subscale scores. The change in BACS composite score was calculated as the BACS composite score at 8 weeks minus the BACS composite score at baseline. (NCT01696929)
Timeframe: Change in BACS composite score from baseline to 8 weeks
| Intervention | Change in BACS Composite Score (Mean) |
|---|---|
| Tocilizumab | 0.7 |
The Positive and Negative Symptoms Scale (PANSS) is the metric used to characterize psychotic symptoms in this study. The PANSS consists of 30 items, each scored 1-7. The range for the PANSS total score is 30-210. There are 3 subscales - PANSS positive score (range 7-49), PANSS negative score (range 7-49), and PANSS general score (range 16-112). PANSS total score is the summation of these 3 subscales. Higher values for the total and subscale scores reflect more severe psychopathology. A positive change in PANSS total score reflects an increase in psychopathology. A negative change in PANSS total score reflects a decrease in psychopathology. (NCT01696929)
Timeframe: Change in PANSS total score from baseline to 8 weeks
| Intervention | Change in PANSS Total Score (Mean) |
|---|---|
| Tocilizumab | -2.6 |
5 reviews available for kynurenine and Psychoses
| Article | Year |
|---|---|
Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies.
Topics: Cognition; Humans; Kynurenic Acid; Kynurenine; Psychotic Disorders; Quality of Life; Schizophrenia | 2023 |
Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies.
Topics: Cognition; Humans; Kynurenic Acid; Kynurenine; Psychotic Disorders; Quality of Life; Schizophrenia | 2023 |
Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies.
Topics: Cognition; Humans; Kynurenic Acid; Kynurenine; Psychotic Disorders; Quality of Life; Schizophrenia | 2023 |
Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies.
Topics: Cognition; Humans; Kynurenic Acid; Kynurenine; Psychotic Disorders; Quality of Life; Schizophrenia | 2023 |
Effects of inflammation on the kynurenine pathway in schizophrenia - a systematic review.
Topics: Humans; Inflammation; Kynurenine; Psychotic Disorders; Schizophrenia | 2020 |
Metabolomics in patients with psychosis: A systematic review.
Topics: 3-Hydroxybutyric Acid; Aspartic Acid; Biomarkers; Bipolar Disorder; Creatine; Female; Glutamic Acid; | 2018 |
[Kynurenines in pathogenesis of endogenous psychiatric disorders].
Topics: Humans; Hydroxyindoleacetic Acid; Kynurenine; Mental Disorders; Psychotic Disorders; Tryptophan; Xan | 2013 |
COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Cyclooxygenase 2 Inhibitors; Cytokines; Depres | 2010 |
COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Cyclooxygenase 2 Inhibitors; Cytokines; Depres | 2010 |
COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Cyclooxygenase 2 Inhibitors; Cytokines; Depres | 2010 |
COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Cyclooxygenase 2 Inhibitors; Cytokines; Depres | 2010 |
1 trial available for kynurenine and Psychoses
| Article | Year |
|---|---|
3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chromatography, High Pressu | 2011 |
10 other studies available for kynurenine and Psychoses
| Article | Year |
|---|---|
Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology.
Topics: Astrocytes; Depression; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Psychotic Di | 2022 |
Autoimmune Concept of Schizophrenia: Historical Roots and Current Facets.
Topics: Antipsychotic Agents; Humans; Kynurenic Acid; Kynurenine; Psychotic Disorders; Schizophrenia | 2021 |
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia.
Topics: Adolescent; Adult; Cytokines; Female; Humans; Kynurenic Acid; Kynurenine; Male; Middle Aged; Psychot | 2018 |
State-associated changes in longitudinal [
Topics: Adult; Age Factors; Brain; Case-Control Studies; Cytokines; Fluorine Radioisotopes; Gray Matter; Hum | 2019 |
Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis.
Topics: Adolescent; Adult; Disease Progression; Female; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Ky | 2019 |
Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders.
Topics: Adolescent; Adult; Bipolar Disorder; Female; Humans; Kynurenine; Male; Metabolic Networks and Pathwa | 2020 |
Tryptophan pathway alterations in the postpartum period and in acute postpartum psychosis and depression.
Topics: Adult; Depression, Postpartum; Female; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Kynurenine; | 2016 |
Kynurenine pathway in psychosis: evidence of increased tryptophan degradation.
Topics: Adult; Chromatography, High Pressure Liquid; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indo | 2009 |
TRYPTOPHAN METABOLISM IN PSYCHOTIC CHILDREN. A PRELIMINARY REPORT.
Topics: Amino Acids; Child; Humans; Hydrolases; Kynurenine; Mental Disorders; Psychotic Disorders; Pyridoxin | 1965 |